PHOENIX, AZ – November 11, 2025 — CND Life Sciences, a pioneering neurodiagnostic company, announced that its Syn-One® Biomarker Services were successfully utilized in a Phase 2 clinical trial to evaluate a novel therapeutic approach for Parkinson’s disease, marking a significant milestone in the clinical application of peripheral tissue biomarkers. The company’s biomarker platform was used to quantify phosphorylated alpha-synuclein (P-SYN) in skin biopsies, serving as an exploratory endpoint to evaluate the therapy’s potential disease-modifying effects. This milestone underscores CND Life Sciences’ growing role as a leading partner for biotech and pharmaceutical companies seeking biomarker-driven insights in neurodegenerative disease research.
Science Significance
The scientific importance of this milestone lies in its validation of peripheral tissue biomarkers as a practical and minimally invasive approach to studying neurodegenerative diseases. The Syn-One Test® detects abnormal deposits of phosphorylated alpha-synuclein (P-SYN) in nerve fibers found within small skin biopsies, providing direct biological evidence of synuclein pathology without the need for invasive brain tissue sampling. This technology addresses one of the biggest challenges in neurology — the lack of accessible biomarkers that accurately reflect disease activity in living patients. The Phase 2 results confirmed that skin-based alpha-synuclein measurement can serve as a surrogate marker for central nervous system pathology, potentially transforming how neurologists diagnose, monitor, and evaluate responses to treatment in Parkinson’s and related disorders. This approach bridges the gap between bench research and bedside diagnostics, aligning with the broader scientific shift toward precision neurology and biological disease staging.
Regulatory Significance
From a regulatory standpoint, the use of biomarker endpoints such as those provided by CND Life Sciences represents an important advancement in clinical trial design for neurodegenerative diseases. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), have emphasized the need for validated biomarkers to accelerate the development and approval of disease-modifying therapies. CND’s data-driven approach supports these initiatives by providing quantifiable and reproducible measures of pathological change that can be incorporated into regulatory submissions. The company’s biomarker services are performed in CLIA-certified laboratories, ensuring full compliance with Good Clinical Laboratory Practice (GCLP) standards. As regulators increasingly integrate biomarker validation into their frameworks, the successful use of the Syn-One Test® in a Phase 2 setting may pave the way for qualification as a recognized biomarker endpoint, expediting future Parkinson’s drug approvals.
Business Significance
Advertisement
Commercially, this collaboration strengthens CND Life Sciences’ position as a preferred biomarker services partner for biotech and pharmaceutical companies engaged in neurodegenerative research. The global Parkinson’s therapeutics and diagnostics market is projected to exceed $12 billion by 2030, driven by rising disease prevalence and growing demand for precision-medicine solutions. CND’s proprietary technology offers competitive differentiation by combining histopathological precision with scalable laboratory throughput, allowing sponsors to integrate biological readouts efficiently into their clinical programs. The company’s growing biomarker services portfolio also supports partnerships across Alzheimer’s, Lewy body dementia, and multiple system atrophy research — expanding its footprint in neurological drug development. With an increasing number of sponsors seeking biomarker-enabled clinical endpoints, CND’s platform is poised for both scientific and commercial expansion.
Patients’ Significance
For patients and clinicians, this breakthrough represents a potential paradigm shift in Parkinson’s disease management. Currently, diagnosis and treatment monitoring rely primarily on clinical observation, with limited tools to measure disease progression objectively. The integration of skin-based biomarker testing provides physicians with a quantifiable biological measure that can confirm diagnosis earlier and evaluate the impact of emerging therapies more accurately. This not only enhances patient selection and monitoring in clinical trials but could ultimately enable personalized treatment strategies once validated in clinical practice. By reducing diagnostic uncertainty and supporting early intervention, CND’s Syn-One Test® has the potential to significantly improve patient outcomes and quality of life.
Policy Significance
The successful incorporation of peripheral biomarkers in Parkinson’s clinical research supports broader health policy objectives aimed at advancing precision medicine and accelerating neurological innovation. National and international policy frameworks — including the U.S. National Plan to Address Parkinson’s Disease and the EU Brain Health Initiative — emphasize the need for biomarker integration into research and clinical care to improve early detection and therapeutic evaluation. CND Life Sciences’ work directly contributes to these priorities by providing a validated, scalable, and non-invasive biomarker platform. The technology also complements public-private initiatives focused on biomarker standardization and data interoperability, ensuring that new diagnostic tools meet ethical, regulatory, and technical standards for widespread clinical adoption.
The successful deployment of CND Life Sciences’ Syn-One® Biomarker Services in a Phase 2 Parkinson’s disease trial marks a pivotal step forward in clinical neuroscience and biomarker-driven medicine. By bridging laboratory innovation with real-world clinical applications, CND is helping redefine how neurodegenerative diseases are diagnosed and monitored. As the company continues to collaborate with pharmaceutical sponsors and regulatory agencies, its technology is poised to play a central role in advancing disease-modifying therapies and precision diagnostics that could transform the future of neurological care.
Source: CND Life Sciences press release
